Clinical trials: Solid Tumors, Advanced Solid Tumors
Solid Tumor
A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.
This was a clinical study with an orally administered drug, BDTX-189 in participants with advanced solid tumors that had select mutations or alterations in human epidermal growth factor receptor 2 (HER2/ErbB2) genes or epidermal…
- Trial name
- MasterKey-01 (NCT04209465)
- Testing
- BDTX-189
- Where
- 38 sites in United States, Denmark and 2 more
- Volunteers
- 91 people
- Sponsor
- Black Diamond Therapeutics, Inc.
Tumor, Tumor, Solid
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes
- Conditions
- Tumor, Tumor, Solid, Metastasis, Metastatic Cancer
- Trial name
- NCT05103358
- Testing
- nab-sirolimus
- Where
- 166 sites in United States, Puerto Rico and 1 more
- Volunteers
- 128 people
- Sponsor
- Aadi Bioscience, Inc.
Neoplasms
Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma
First in human, open-label, dose escalation (Phase I) and expansion study (Phase 2a) of oral lisavanbulin (BAL101553) in adult patients with advanced solid tumors and adult patients with recurrent or progressive glioblastoma…
- Trial name
- NCT02490800
- Testing
- Lisavanbulin Phase 1 dose escalation portion, Lisavanbulin Phase 2a expansion portion
- Where
- 13 sites in Belgium, Germany and 2 more
- Volunteers
- 72 people
- Sponsor
- Basilea Pharmaceutica
Advanced Cancer, Advanced Solid Tumors
Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors
The study is being conducted to determine the maximum tolerated dose, overall safety and tolerability profile, and pharmacokinetic profile of CP-751,871 and sunitinib when given in combination with advanced solid tumors.
- Trial name
- NCT00729833
- Testing
- CP-751,871, Sunitinib
- Where
- 4 sites in United States
- Volunteers
- 45 people
- Sponsor
- Pfizer
Advanced Solid Tumor
Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate BMS-986315 alone and in combination with nivolumab or cetuximab in participants with advanced solid tumors.
- Trial name
- NCT04349267
- Testing
- BMS-986315, nivolumab, cetuximab
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 44 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Colorectal Cancer
Sym004 in Patients With Advanced Solid Tumors
This trial is designed as a multi-centre, open label, dose-escalation, phase I trial and consists of five parts.
- Trial name
- NCT01117428
- Testing
- Sym004
- Where
- 7 sites in United States, Belgium and 1 more
- Volunteers
- 111 people
- Sponsor
- Symphogen A/S
Select Advanced Solid Tumors
Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers
IMCnyeso is a bispecific fusion protein designed for the treatment of cancers that express NY-ESO-1 and/or LAGE-1A. This was a first-in-human trial designed to evaluate the safety and efficacy of IMCnyeso in HLA-A*02:01-positive…
- Trial name
- NCT03515551
- Testing
- IMCnyeso
- Where
- 12 sites in United States, Canada and 1 more
- Volunteers
- 29 people
- Sponsor
- Immunocore Ltd
Solid Tumor, Metastatic Bladder Cancer
Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies
The purpose of this study is to determine the maximum tolerated dose of RX-3117 in subjects with advanced or metastatic solid tumors (Phase 1).
- Trial name
- NCT02030067
- Testing
- RX-3117
- Where
- 12 sites in United States
- Volunteers
- 127 people
- Sponsor
- Processa Pharmaceuticals
Unspecified Adult Solid Tumor, Protocol Specific
Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies
This clinical trial studies capecitabine and celecoxib in treating patients with solid malignancies that are metastatic or cannot be removed by surgery.
- Trial name
- NCT01705106
- Testing
- capecitabine, celecoxib, pharmacological study
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Chicago
Cancer
OLAParib COmbinations
The primary objective of this phase II trial is to determine tumor overall response rate (ORR) in molecularly selected patients with measurable disease as assessed by the Response Evaluation Criteria in Solid Tumors (RECIST)…
- Trial name
- OLAPCO (NCT02576444)
- Testing
- AZD2281, AZD5363, AZD1775
- Where
- 4 sites in United States
- Volunteers
- 67 people
- Sponsor
- Joseph Paul Eder
Advanced Non-Hematologic Malignancies
CP-751,871 In Combination With Docetaxel In Advance Non-hematologic Malignancies
This clinical trial is designed to determine the safety, tolerability, pharmacokinetics and pharmacodynamic effects of escalating doses of CP 751,871 given in combination with docetaxel in patients with non-hematologic…
- Trial name
- NCT01653158
- Testing
- CP-751,871, Docetaxel
- Where
- United Kingdom
- Volunteers
- 46 people
- Sponsor
- Pfizer
Lymphoma, Non-Hodgkin, Neoplasms
A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
Study CC-90011-ST-001 is an open-label, Phase 1, dose escalation and expansion, First-In-Human (FIH) clinical study of CC-90011 in subjects with advanced unresectable solid tumors (enriched for grade 2 NENs, grade 2 NETs and…
- Trial name
- NCT02875223
- Testing
- CC-90011, Rifampicin, Itraconazole
- Where
- 15 sites in France, Italy and 3 more
- Volunteers
- 75 people
- Sponsor
- Celgene
Locally Advanced or Metastatic Solid Tumors
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
The primary objective of this study was to determine the safety and tolerability of pamiparib, the maximum tolerated dose (MTD) or maximum administered dose (MAD) for pamiparib combined with TMZ, to select the recommended Phase 2…
- Trial name
- NCT03150810
- Testing
- Pamiparib, Temozolomide
- Where
- 22 sites in United States, Australia and 2 more
- Volunteers
- 139 people
- Sponsor
- BeiGene
Ovarian Neoplasms, Neoplasms
Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients
Niraparib (Zejula®)is extensively metabolized and eliminated primarily by hepatic and renal pathways. The purpose of this study is to evaluate pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment…
- Conditions
- Ovarian Neoplasms, Neoplasms, Solid Tumor, Hepatic Impairment
- Trial name
- NCT03359850
- Testing
- Niraparib
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- Tesaro, Inc.
Advanced Solid Tumors
Phase I Study of Intravenous Lipotecan® (TLC388 HCl for Injection) in Patients With Advanced Solid Tumors
The purpose of this study is to find a safe and tolerable dose of Lipotecan® when administered to patients with advanced solid tumors.
- Trial name
- NCT00747474
- Testing
- Lipotecan
- Where
- 4 sites in United States, Taiwan
- Volunteers
- 54 people
- Sponsor
- Taiwan Liposome Company
Cancer
Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors
This is a dose escalation safety study of birinapant (TL32711) in combination with chemotherapy in subjects with advanced or metastatic solid tumors.
- Trial name
- NCT01188499
- Testing
- Birinapant
- Where
- 7 sites in United States
- Volunteers
- 176 people
- Sponsor
- TetraLogic Pharmaceuticals
Advanced Solid Malignancies
Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies
This is a modular, Phase I/II, multicentre study to investigate CT7001 monotherapy in advanced solid malignancies and to further investigate CT7001 as monotherapy or in combination with standard therapy in specific participant…
- Trial name
- NCT03363893
- Testing
- CT7001, Fulvestrant
- Where
- 23 sites in United States, United Kingdom
- Volunteers
- 124 people
- Sponsor
- Carrick Therapeutics Limited
Metastatic Solid Tumors
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study
This retrospective study has a primary objective to estimate the incidence of NTRK gene fusion depending on the histological diagnosis.
- Trial name
- NTRK (NCT04010240)
- Testing
- No intervention (this is a retrospective cohort study)
- Where
- France
- Volunteers
- 3,820 people
- Sponsor
- Institut Bergonié
Ovarian Cancer, Fallopian Tube Cancer
A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)
Part 1 (Completed Enrollment) - The purpose of the first part of the study was to evaluate the safety of different doses and dosing regimens of oral rucaparib administered daily to patients with solid tumors.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Advanced Solid Tumor With Evidence of Germline or Somatic BRCA
- Trial name
- NCT01482715
- Testing
- Rucaparib
- Where
- 16 sites in United States, Canada and 3 more
- Volunteers
- 136 people
- Sponsor
- pharmaand GmbH
Breast Neoplasms, Prostate Neoplasms
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
A Phase 1 dose escalation and expansion study evaluating safety, tolerability and pharmacokinetics of PF-06952229 in adult patients with advanced solid tumors.
- Conditions
- Breast Neoplasms, Prostate Neoplasms, Neoplasms, Squamous Cell, Melanoma
- Trial name
- NCT03685591
- Testing
- PF-06952229, Enzalutamide
- Where
- 15 sites in United States
- Volunteers
- 49 people
- Sponsor
- Pfizer